<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440592</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-G02</org_study_id>
    <nct_id>NCT04440592</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic&#xD;
      sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in&#xD;
      Diffuse Systemic Sclerosis (ACR CRISS) at Week 52&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ACR CRISS composite score (0-1) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The comparison between MT-7117 treatment group and placebo group will be performed. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT 7117 treatment for up to 52 weeks using the Health Assessment Questionnaire Disability Index (HAQ DI). The Health Assessment Questionnaire Disability Index (HAQ-DI) is a self-administered instrument consists of 20 questions referring to eight component sets consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored on a 4-point scale from 0 to 3: 0 = Without any difficulty; 1 = With some difficulty; 2 = With much difficulty; 3 = Unable to do. Overall score was computed as the sum of component set scores and divided by the number of component sets answered. This outcome measure represents the change in mean score from baseline. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent predicted forced vital capacity (%pFVC) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks on pulmonary function as measured by percent predicted forced vital capacity (%pFVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Patient Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the Physician Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Rodnan Skin Score (mRSS) from baseline from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using the modified Rodnan Skin Score (mRSS). mRSS evaluates a subject's skin thickness which will be assessed by palpation and rated using an mRSS that ranges from 0 (normal) to 3 (severe skin thickening) across 17 different body sites. The total score is the sum of the individual skin scores from all of these sites and ranges from 0 to 51 units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR CRISS Score up to Week 39</measure>
    <time_frame>39 weeks</time_frame>
    <description>To evaluate the efficacy of MT 7117 treatment for up to 39 weeks using the ACR CRISS Score. The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in mRSS, FVC % predicted, physician and patient global assessments, and HAQ-DI. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR CRISS score responder (CRISS&gt;=0.6) from baseline up to week 52</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the efficacy of MT-7117 treatment for up to 52 weeks using CRISS Score. Subjects with CRISS score is &gt;=0.60 are considered improved, while subjects with CRISS score &lt; 0.60 are considered not improved.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>MT-7117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet of MT-7117 once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet of placebo once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <description>MT-7117</description>
    <arm_group_label>MT-7117</arm_group_label>
    <other_name>Dersimelagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Additional screening criteria check may apply for qualification.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet all the following criteria will be considered eligible to&#xD;
             participate in the study:&#xD;
&#xD;
               1. Must provide signed and dated informed consent form (ICF) to participate in the&#xD;
                  study. Subjects must be able to (in the judgment of the Investigator) understand&#xD;
                  the nature of the study and all risks involved with participation in the study.&#xD;
                  Subjects must be willing to cooperate and comply with all protocol restrictions&#xD;
                  and procedures including study visits.&#xD;
&#xD;
               2. Male or female aged 18 to 75 years inclusive at screening with documented&#xD;
                  diagnosis of systemic sclerosis (SSc), as defined using the 2013 ACR/European&#xD;
                  League Against Rheumatism (EULAR) criteria.&#xD;
&#xD;
               3. Has diffuse cutaneous form of SSc according to Leroy and Medsger's criteria.&#xD;
&#xD;
               4. Disease duration ≤ 3 years from the first non-Raynaud's phenomenon manifestation.&#xD;
&#xD;
               5. Has an mRSS of 15 to 45 units at screening and have clinical skin involvement&#xD;
                  proximal and distal to the elbows, knees, or both or any truncal involvement,&#xD;
                  with or without face involvement.&#xD;
&#xD;
               6. If disease duration is &gt; 18 months defined as time from the first non Raynaud&#xD;
                  phenomenon manifestation, subject must fulfill at least 1 of the criteria listed&#xD;
                  below that are indicatives of active disease at screening:&#xD;
&#xD;
                    1. A documentation of new skin involvement that occurred within the past 9&#xD;
                       months, or&#xD;
&#xD;
                    2. Increase in mRSS ≥ 3 units within the past 9 months, or&#xD;
&#xD;
                    3. Presence of TFRs or,&#xD;
&#xD;
                    4. C- reactive protein (CRP) ≥ 6 mg/L, or&#xD;
&#xD;
                    5. Erythrocyte sedimentation rate ≥ 28 mm/hr, or&#xD;
&#xD;
                    6. Platelet count ≥ 330 x 10^9/L (330,000/microliter).&#xD;
&#xD;
                  NOTE: Investigator should exclude all other acute intercurrent illness if&#xD;
                  subjects fulfilling laboratory criteria (d, e, f) only.&#xD;
&#xD;
               7. Willing to follow restrictions regarding concomitant medications that are&#xD;
                  described.&#xD;
&#xD;
               8. Female subjects who are non-lactating and have a negative urine pregnancy test at&#xD;
                  baseline visit prior to receiving the first dose of study drug.&#xD;
&#xD;
               9. Female subjects of childbearing potential and male subjects with partner of&#xD;
                  child-bearing potential currently using/willing to use 2 effective methods of&#xD;
                  contraception including barrier method as described.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will be excluded from the study if any of the following criteria apply:&#xD;
&#xD;
               1. Has a history or presence of rheumatic autoimmune diseases other than dcSSc&#xD;
                  unless the dominant features of the disease are dcSSc, as determined by the&#xD;
                  Investigator.&#xD;
&#xD;
               2. Has a pulmonary disease with FVC ≤ 50% of predicted or diffusion capacity of the&#xD;
                  lung for carbon monoxide [DLco] ≤ 45% of predicted (hemoglobin corrected) at time&#xD;
                  of screening&#xD;
&#xD;
               3. Has a diagnosis of clinically significant resting pulmonary hypertension (if&#xD;
                  exceeding estimated right ventricular systolic pressure of &gt; 40 mmHg estimated by&#xD;
                  transthoracic echocardiography [unless the right heart catheterization is normal&#xD;
                  within the last 6 months] or mean pulmonary artery pressure &gt; 30 mmHg as measured&#xD;
                  by right heart catheterization) and requires treatment with more than one oral&#xD;
                  medication.&#xD;
&#xD;
               4. Has a cardiac abnormality such as left ventricular failure with ejection fraction&#xD;
                  &lt; 45%, significant arrhythmia, congestive heart failure (New York Heart&#xD;
                  Association Class II-IV), unstable angina, uncontrolled hypertension, or&#xD;
                  symptomatic pericardial effusion at screening.&#xD;
&#xD;
               5. Has a history of myocardial infarction in the last 26 weeks prior to screening.&#xD;
&#xD;
               6. Has a history of renal crisis within the past 52 weeks prior to screening.&#xD;
&#xD;
               7. Has a documented history of chronic kidney disease [ stage 3b-5, an estimated&#xD;
                  glomerular filtration rate (eGFR) &lt; 45 ml/min at screening], or any episode of&#xD;
                  acute kidney injury treated with or without dialysis.&#xD;
&#xD;
               8. Has a presence of clinically significant hepatobiliary disease based on Liver&#xD;
                  Function Test (LFT) values at screening: e.g. aspartate aminotransferase (AST),&#xD;
                  alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≥ 3.0 × upper limit of&#xD;
                  normal (ULN), or total bilirubin &gt; 1.5 × ULN at screening.&#xD;
&#xD;
               9. Has a history or presence of clinically significant disease not related to SSc&#xD;
                  [neurologic, renal, endocrinal, gastrointestinal cardiovascular, hepatic,&#xD;
                  dermatologic, hematological, musculoskeletal, genitourinary, thromboembolic,&#xD;
                  advanced arteriosclerosis, hyperthyroidism, moderate to severe hypertension,&#xD;
                  immunologic disease, pulmonary (e.g., uncontrolled asthma, emphysema, chronic&#xD;
                  obstructive pulmonary disease) or any other disorder] as determined by the&#xD;
                  Investigator at screening. Conditions deemed not-clinically significant according&#xD;
                  to the Investigator's discretion are acceptable.&#xD;
&#xD;
              10. Has a history or presence of psychiatric disease judged to be clinically&#xD;
                  significant by the Investigator and which may interfere with the study evaluation&#xD;
                  and/or safety of the subject.&#xD;
&#xD;
              11. Has any clinically significant disease or laboratory abnormality judged to be&#xD;
                  clinically significant by the Investigator and which may interfere with the study&#xD;
                  evaluation and/or safety of the subject at screening. Laboratory abnormalities&#xD;
                  include but not limited to any of the followings: Hemoglobin &lt; 9 g/dL; WBC &lt;&#xD;
                  3,000/mm3 (&lt; 3 x 10^9/L); platelets &lt; 100,000/mm3 (&lt;100 x 10^9/L).&#xD;
&#xD;
              12. Has a history of positive hepatitis B surface antigen, hepatitis C antibody,&#xD;
                  except for documented cure for the hepatitis B virus (HBV), defined as sustained,&#xD;
                  undetectable HBsAg and HBV DNA in serum and adequately treated hepatitis C virus&#xD;
                  (HCV) with documentation of sustained virologic response defined as undetectable&#xD;
                  HCV RNA at least 12 weeks after the end of treatment.&#xD;
&#xD;
              13. Has a history of positive human immunodeficiency virus (HIV)&#xD;
&#xD;
              14. Has a history of melanoma, familial melanoma (defined as having 2 or more&#xD;
                  first-degree relatives, such as parent, sibling, and/or child), or presence of&#xD;
                  melanoma and/or lesions suspicious for melanoma at screening.&#xD;
&#xD;
              15. Has a presence of squamous cell carcinoma, basal cell carcinoma, or other&#xD;
                  malignant skin lesions. Any suspicious lesions or nevi (Melanocytic Lesions) will&#xD;
                  be evaluated. If the suspicious lesion or nevi (Melanocytic Lesions) cannot be&#xD;
                  resolved through biopsy or excision, the subject will be excluded from the study.&#xD;
&#xD;
              16. Has history of any other malignancy(ies) in the last 5 years with the exception&#xD;
                  of cervical carcinoma in situ.&#xD;
&#xD;
              17. Has a history or planning to receive cell-depleting therapy or bone marrow&#xD;
                  transplantation during study treatment period.&#xD;
&#xD;
              18. Has a history of ultraviolet (UV) phototherapy within 6 weeks prior to screening&#xD;
                  or planning to receive UV phototherapy during study treatment period.&#xD;
&#xD;
              19. Treatment of SSc disease with&#xD;
&#xD;
                    1. Cyclophosphamide, rituximab, or cyclosporine received within 26 weeks prior&#xD;
                       to screening.&#xD;
&#xD;
                    2. Small molecules such as JAK inhibitors (e.g., tofacitinib) received within&#xD;
                       12 weeks prior to screening.&#xD;
&#xD;
                    3. Pirfenidone received within 12 weeks prior to screening.&#xD;
&#xD;
                    4. Infliximab, certolizumab, golimumab, adalimumab, abatacept, tocilizumab&#xD;
                       within 10 weeks prior to screening.&#xD;
&#xD;
                    5. Etanercept within 4 weeks prior to screening.&#xD;
&#xD;
                    6. Oral, intravenous, or intramuscular corticosteroids (prednisone &gt; 10 mg/day&#xD;
                       or equivalent) received within 30 days prior to screening&#xD;
&#xD;
                    7. Nintedanib within 12 weeks prior to screening.&#xD;
&#xD;
                    8. More than 1 of the immunosuppressant therapy listed below, has changed&#xD;
                       medication within 12 weeks prior to screening, or not on a stable dose of&#xD;
                       the same medication for at least 12 weeks prior to screening.&#xD;
&#xD;
                    9. Hydroxychloroquine (up to 400 mg/day), or ii. Mycophenolate (up to 3 g/day),&#xD;
                       or iii. Mycophenolic acid (up to 2.14 g/day), or iv. Methotrexate (up to 25&#xD;
                       mg/Week), or v. Leflunomide (up to 20 mg/day), or vi. Azathioprine (up to 3&#xD;
                       mg/kg/day).&#xD;
&#xD;
              20. Treatment with afamelanotide or other MC1R agonist within 12 weeks before&#xD;
                  screening (Visit 1).&#xD;
&#xD;
              21. Treatment with any drugs or supplements which, in the opinion of the&#xD;
                  Investigator, may interfere with the objectives of the study or safety of the&#xD;
                  subject.&#xD;
&#xD;
              22. Has previously exposed to MT 7117 (this does not include placebo treated&#xD;
                  subjects).&#xD;
&#xD;
              23. Has previously treated with any investigational agent within 12 weeks prior to&#xD;
                  screening OR 5 half-lives of the investigational product (whichever is longer).&#xD;
&#xD;
              24. Female subjects who are pregnant, lactating, or intending to become pregnant&#xD;
                  during the study.&#xD;
&#xD;
              25. Has a positive autoantibody status of anti-centromere antibody.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>information@mt-pharma-us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arizona Arthritis Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UCSD School of Medicine</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Care Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Board of Trustees of the Leland Stanford Junior University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine - The Anlyan Center (TAC) for Medical Research &amp; Education</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GNP Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GNP Research</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatology Center of Oklahoma, PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103-2600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Skin Cancer Consultants</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shelby Research, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Olympus Medical Group Research, LLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaam Gewest</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital, The Rebecca Macdonald Centre For Arthritis And Autoimmune Disease</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuettemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIRI, Centrum fur innovative Diagnostik und Therapie Rheumatologie und Immunologie (GmbH) Am Klinikum der Johann Wolfgang Goethe-Universitat</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinium Bad Bramstedt</name>
      <address>
        <city>Bad Bramstedt</city>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internistisches Zentrum des Universitaetsklinikums Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ferrara Azienda Ospedaliero-Universitaria Sant' Anna</name>
      <address>
        <city>Cona</city>
        <state>Ferrera</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Milano - Azienda Ospedaliera Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento Medicina E Immunologia Clinica, Irccs</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SOD Reumatologia -AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapienza Universita di Roma, UOC di Medicina Interna e Nutrizione Clinica-Scleroderma Unit. Università La Sapienza, Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Kliniczne</name>
      <address>
        <city>Krakow</city>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmanska</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Best Solutions Sp. z o.o. Sp.K</name>
      <address>
        <city>Warszawa</city>
        <zip>02-793</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut d'Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital - Liverpool University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Leeds - Leeds Institute of Biomedical</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital - Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

